KR20140111901A - Novel PNA and antibacterial composition comprising the same - Google Patents

Abstract

The present invention relates to a novel peptide nucleic acid (PNA), a PNA-peptide composite, an antibacterial composition containing the PNA-peptide composite as an active ingredient, and a pharmaceutical composition containing the antibacterial composition to prevent and treat bacterial infectious diseases. The PNA-peptide composite, according to the present invention, has an outstanding antibiotic and antibacterial activation against gram-positive bacteria and gram-negative bacteria, thus the PNA-peptide composite can be usefully applied as antibacterial compositions and medicine for bacterial infectious diseases.

Description

[0001] The present invention relates to novel PNAs and antibacterial compositions comprising them,

The present invention relates to a novel antibacterial composition comprising a peptide nucleic acid (PNA), a PNA-peptide complex, a PNA-peptide complex as an active ingredient, and a pharmaceutical composition for preventing or treating a bacterial infectious disease .

The development gained from the discovery and development of antibiotics in modern medicine was very revolutionary, but continued abuse could not prevent the emergence of antibiotic-resistant bacteria. In the case of diseases caused by accumulated antibiotic resistant pathogenic bacteria, it is impossible to treat them with the existing antibiotics. Therefore, there is an active research on anti-bacterial or anti-infective strategies of new mechanisms that can go beyond the limits of existing antibiotics worldwide.

As a representative strategy, a method using an antisense effect that suppresses expression of a specific gene of pathogenic bacteria, which is a kind of artificially synthesized nucleic acid, PNA (peptide nucleic acid), has been proposed.

PNAs are similar to oligonucleotides and oligonucleotide analogs and can mimic DNA and RNA. PNA has been replaced by a pseudo-peptide backbone in the deoxyribose backbone of DNA (Nieslsen et al., Science, 1991, 254, 1475). Each subunit or monomer present in the PNA has a natural or non-natural nucleobase attached to the backbone. One skeleton is composed of repeating units of N- (2-aminoethyl) glycine linked through an amide bond. PNAs hybridize with complementary nucleic acids through the Watson and Creek base pairs and form spirals (Egholm et al., Nature, 1993, 365, 566). PNA binds to both DNA and RNA to form PNA / DNA or PNA / RNA double-stranded bodies. The PNA / DNA or PNA / RNA double-stranded body is bound to a larger affinity than the corresponding DNA / DNA or RNA / RNA double-stranded body when determined by Tms. The thermal stability of the PNA / DNA or PNA / RNA duplex may be due to the lack of charge repulsion in the neutral skeleton of the PNA. Not only does the affinity increase, but PNA hybridizes to DNA with higher specificity compared to DNA / DNA.

However, there have been few studies on antibiotic and antimicrobial PNAs against a wide range of strains.

Accordingly, the present inventors have designed a novel PNA targeting a gene essential to major pathogenic bacteria, prepared a PNA-peptide complex in which PNA was fused with a peptide, and then, the PNA-peptide complex was identified as a Gram- And exhibits a wide range of antibiotic and antimicrobial activities.

It is an object of the present invention to provide a novel peptide nucleic acid (PNA).

Yet another object of the present invention is to provide a PNA-peptide complex.

It is still another object of the present invention to provide an antimicrobial composition comprising the PNA-peptide complex as an active ingredient.

It is still another object of the present invention to provide a pharmaceutical composition for preventing or treating a bacterial infectious disease comprising the above antimicrobial composition.

In order to achieve the above object, the present invention provides a novel PNA (peptide nucleic acid) represented by one or more base sequences selected from the group consisting of SEQ ID NOS: 1 to 7.

The present invention also provides a PNA-peptide complex.

The present invention also provides a composition for antimicrobial use comprising the PNA-peptide complex as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for preventing or treating a bacterial infection disease comprising the above antimicrobial composition.

The PNA-peptide complex according to the present invention has excellent antibiotic and antimicrobial activity against Gram-positive bacteria and Gram-negative bacteria, and thus can be usefully used as an antimicrobial composition and a therapeutic agent for a bacterial infection disease.

Brief Description of the Drawings Figure 1 shows the antisense effect of Staphylococcus aureus in various P-PNA complexes according to the present invention.
Figure 2 shows the minimum effective concentration of Staphylococcus aureus in various P-PNA complexes according to the present invention.
3 is a graph showing the antibiotic effect of various P-PNA complexes on Gram-positive bacteria according to the present invention.
FIG. 4 is a graph showing the antibiotic effect of various P-PNA complexes against Gram-negative bacteria according to the present invention.

Hereinafter, the present invention will be described in more detail.

The present invention provides a novel PNA (peptide nucleic acid) represented by one or more base sequences selected from the group consisting of SEQ ID NOS: 1-7.

In the present invention, PNA means a peptide nucleic acid, which is a DNA-like compound in which a deoxyribose phosphate backbone is substituted with a peptide oligomer. The structure of conventional PNAs known in the art is that N- (2-aminoethyl) glycine units are repeatedly linked by an amide bond to form an N- (2-aminoethyl) glycine skeleton And the nucleic acid bases such as purin (A and G) and pyrimidine (C and T) bases are connected to the skeleton through methylene carbonyl bonds.

The present invention also provides a PNA-peptide complex represented by the following formula (1).

[Formula 1]

PNA-L-peptide

In the above formula (1), PNA is a peptide nucleic acid represented by at least one base sequence selected from the group consisting of SEQ ID NOS: 1 to 7,

L is a linker or a bond,

Wherein the peptide is represented by C- (BA) nD, wherein A is an uncharged amino acid or an amino acid analogue, B is one to three positively charged amino acids or amino acid analogues, and C is 0 to 4 Uncharged amino acid or amino acid analog, D is 0 to 3 positively charged amino acid or amino acid analog, and n is an integer of 1 to 10.

KFFKFFKFF (SEQ ID NO: 9), KFFKFFKF (SEQ ID NO: 10), KFFKFFK (SEQ ID NO: 11), KFFKFF (SEQ ID NO: 12), and KFFKFFKFF KFFKF (SEQ ID NO: 13), KFFK (SEQ ID NO: 14), KFF (SEQ ID NO: 15), FFRFFRFFRRLLR (SEQ ID NO: 16), LLKKLAKAL (SEQ ID NO: 17), KRRWPWWPWKK , LLKLLLKLLLK (SEQ ID NO: 20) and LLKKLAKALK (SEQ ID NO: 21), preferably KFFKFFKFFK (SEQ ID NO: 8), but not limited thereto.

The L may be any linker moiety known to increase the permeability of the cell membrane with a linker or a linkage. It is preferably leucine (L) or glycine (G), more preferably leucine (L).

PNA- peptide complexes of the invention preferably _{Pjyh-cmk1 ((KFF) 3} K ( SEQ ID NO: 8) -L-tcatgcgtca (SEQ ID NO: 1)), ₃ K (SEQ ID NO: 8 Pjyh-deoD1 ((KFF) ) -L-tcatttgtta (SEQ ID NO: 2)), Pjyh-ligA1 ( (KFF) 3 K ( SEQ ID NO: 8) -L-ccatccctta (SEQ ID NO: 5)), ₃ K (SEQ ID NO: 8) Pjyh-pryH1 ((KFF ) -L-ccattttctt (SEQ ID NO: 6)), Pjyh-smpB1 ( (KFF) 3 K ( SEQ ID NO: 8) -L-tcatactcac may be (SEQ ID NO: 7)).

The PNA-peptide complex according to the present invention can be produced by any method known in the art, but is not limited thereto.

The novel PNA-peptide complex according to the present invention has excellent antibiotic and antimicrobial activity against Gram-positive bacteria and Gram-negative bacteria, and thus can be usefully used as an antimicrobial composition and a therapeutic agent for bacterial infectious diseases.

The present invention also provides a composition for antimicrobial use comprising the PNA-peptide complex as an active ingredient.

The antimicrobial composition of the present invention may preferably be a pharmaceutical composition.

The antimicrobial composition is an antibacterial composition for pathogenic microorganisms or resistant bacteria, preferably the antimicrobial composition for a positive bacteria or gram negative gram, more preferably from Staphylococcus aureus (Staphylococcus aureus , Staphylococcus hyicus), Streptococcus discharge galactose tiae (Streptococcus dysgalactiae), Streptococcus Ube-less (Streptococcus uberis), ekuyi Streptococcus (Streptococcus equi ), Streptococcus epidemicus zooepidemicus ), Listeria monocytogenes ( Listeria monocytogenes), Escherichia coli (Escherichia coli , Salmonella Typhimurium, Pseudomonas aeruginosa, aeruginosa , Klebsiella pneumoniae , and the like, but is not limited thereto.

The antimicrobial composition of the present invention may contain not only the PNA-peptide complex of the present invention but also one or more known active ingredients having antimicrobial activity against pathogenic microorganisms or resistant bacteria.

In addition, the antimicrobial composition of the present invention may further comprise a pharmaceutically acceptable carrier.

The term "pharmaceutically acceptable carrier" in the present invention should not lead to the production of antibodies which are harmful to the individual to which the composition is administered, nor should it be toxic. Suitable carriers are large, slowly metabolized macromolecules such as proteins, polypeptides, liposomes, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inert viral particles. For example, pharmaceutically acceptable salts such as mineral acid salts such as hydrochloride, hydrobromide, phosphate and sulfate, or salts of organic acids such as acetate, propionate, malonate and benzoate may be used. In addition, the carrier may additionally contain liquids such as water, saline, glycerol and ethanol.

The antimicrobial composition of the present invention can be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) according to the intended method, and the dose is determined depending on the condition and weight of the patient, The dosage form, the route of administration, and the period of time, it may be appropriately selected by those skilled in the art, for example, about 0.001 mg to 1000 mg may be administered in a form mixed with a pharmaceutically acceptable carrier. The antimicrobial composition of the present invention may be administered once or several times a day, if necessary, and may be used alone or in combination with methods using surgery, hormone therapy, drug therapy, and biological response modifiers.

The antimicrobial composition of the present invention may preferably be a quasi-drug composition. That is, the present invention provides a quasi-drug composition for the purpose of preventing or improving an infectious disease caused by pathogenic microorganisms or resistant bacteria.

The quasi-drug composition of the present invention can be used in combination with other quasi-drugs or quasi-drugs, and can be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). The quasi-drug composition may be, but is not limited to, disinfectant cleaner, shower foam, gagrin, wet tissue, detergent soap, hand wash, humidifier filler, mask, ointment or filter filler.

In addition, the present invention provides a pharmaceutical composition for preventing or treating a bacterial infection disease comprising the above antimicrobial composition.

In the present invention, "prevention" means any action that inhibits or delays infectious diseases caused by the bacteria (pathogenic microorganisms or resistant bacteria) by the administration of the composition. By "treatment" (Microbial pathogens or resistant bacteria) caused by the infectious disease is to improve or to change all means to act.

In the present invention, the microorganism is a pathogenic microorganism for which the parasite invades a living body of animals and plants and raise the bottle, or included in the bacteria of Gram-positive and Gram-negative bacteria, preferably from Staphylococcus aureus (Staphylococcus aureus , Staphylococcus hyicus , Streptococcus dysgalactiae , Streptococcus uberis uberis), ekuyi Streptococcus (Streptococcus equi), Streptococcus main epi Demi kusu (Streptococcus zooepidemicus), L. monocytogenes jeneseu (Listeria monocytogenes), Escherichia coli (Escherichia coli , Salmonella Typhimurium, Pseudomonas aeruginosa, aeruginosa , Klebsiella pneumoniae , and the like.

In the present invention, the resistant microorganism means a bacterium which shows resistance to an antibiotic as a result of continuous use of the drug to treat or prevent any disease and its complications or any bacterial disorder and its complications. Examples of such antibiotics include, but are not limited to, vancomycin, cephalosporin, quinolone and fluoroquinolone, penicillin, betalactamase inhibitor, carbepenem, monobactam, macrolide and lincosamine, glycopeptide, rifampin, oxazolidinone, tetracycline, Aminoglycosides, streptoglumin, and sulfonamides. Antibiotic-resistant bacteria are resistant to the above-mentioned antibiotics and are continuously maintained in the disease. Preferably methicillin-resistant Staphylococcus (MRSA, Methicillin-resistant Staphylococcus aureus ), quinolone-resistant Staphylococcus (QRSA, Quinolone-resistant Staphylococcus aureus), vancomycin-resistant Staphylococcus aureus (VRSA, Vancomycin-resistant Staphylococcus aureus ) or vancomycin-resistant and Tero Rhodococcus (VRE, Vancomycin-resistant Enterococcus) may be.

In the present invention, the bacterial infectious disease is a skin infectious disease, food poisoning, otitis media, cystitis, peritonitis, urinary tract infection, mastitis, pneumonia, endocarditis, conjunctivitis, arthritis, endometritis, Sepsis, acne, and the like.

Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the examples.

Example  One. New PNA  design

First, using DEG (Database of Essential Genes) to select genes essential for the survival of bacteria, the previously known Duffield et . al . A total of 7 genes were selected according to the method of. This is shown in Table 1.

gene protein function cmk cytidylate kinase or cystidine monophosphate kinase ATP + (d) C / UMP → ADP + (d) C / UDP deoD purine nucleoside phosporylase (PNPase) Nucleotide synthesis (inosine) ftsA Cell division protein FtsA early component of the Z-ring required for cell division glmU UDP-N-acetylglucosamine pyrophosphorylase / glucosamine-1-phosphate bifunctional enzyme with acetyltransferase and uridyltransferase activities, essential for the biosynthesis of the bacterial cell wall liga DNA ligase Ligation pryH uridylate kinase UMP kinase catalyzing UMP phosphorylation smpB (small protein B) ssRA (small stable RNA A) -binding protein Required for recycling of ribosomes

The sequence complementary to the gene sequence upstream of the 6 bp upstream of the ribosomal binding region (RBR) including the transcription initiation site of the gene selected in Table 1 was synthesized, and in order to enhance transfection into the cell, The cationic peptide (KFFKFFKFFKL) was fused. The synthesis was carried out in Panagen (Deajeon, Korea) and specific sequence information is shown in Table 2. In Table 2, L of the P-PNA structure is leucine.

P- PNA ID Target gene Target sequence (position) P- PNA  rescue PNA bp Aggregation Pjyh-cmk1 cmk 5'-TGACGC ATG A-3 '
(-6 to +3) (KFF) ₃ KL-tcatgcgtca 10 +++ Pjyh-deoD1 deoD 5'-TAACAA ATG A-3 '
(-6 to +3) (KFF) ₃ KL-TCATTGTTA 10 ++ Pjyh-ftsA2 ftsA 5'-GTGCCTATCT ATG -3 '
(-10 to +2) (KFF) ₃ KL-catagataggcag 13 +++ Pjyh-glmU1 glmU 5'-ATGTTC ATG C-3 '
(-6 to +3) (KFF) ₃ KL-gcatGACACat 10 + Pjyh-ligA1 liga 5'-TAAGGG ATG G-3 '
(-6 to +3) (KFF) ₃ KL-CCcatCCctta 10 0 Pjyh-pryH1 pryH 5'-AAGAAA ATG G-3 '
(-6 to +3) (KFF) ₃ KL-ccattttctt 10 0 Pjyh-smpB1 smpB 5'-GTGAGT ATG A-3 '
(-6 to +3) (KFF) ₃ KL-tcatactcac 10 0

Example  2. Antisense  Verification of effect

P-PNAs designed in Example 1 were introduced into S. aureus strain P-PNA showing strong antisense effect was selected by applying to ATCC29740. More specifically, strain S. aureus ATCC 29740 was cultured in MHB (Mueller Hinton broth, BD) medium at 37 ° C for 18 hours and then diluted 1: 10000 in fresh MHB medium. P-PNA (stock solution, 400 μM in DW) was added to the diluent to a final concentration of 40 μM, followed by shaking incubation at 37 ° C. After 4 hours and 8 hours, the bacterial solution was partially taken and used for the spot test. The spot test was performed by dropping 5 μl of the diluted bacterial solution in MHA (Mueller Hinton agar), which had been diluted 10 times from the stock solution, followed by culturing at 37 ° C for 18 hours and observing the number of colonies. The results are shown in Fig.

As shown in Fig. 1, the effects of Pjyh-cmk1 and Pjyh-deoD1 of the present invention were the most excellent, and Pjyh-ligA1, Pjyh-pryH1 and Pjyh-smpB1 also had a definite antisense effect.

Example  3. Determination of minimum effective concentration

Pjyh-cmk1, Pjyh-deoD1, and Pjyh-smpB1 among the P-PNAs exhibiting excellent antisense effect in Example 2 were selected to obtain the minimum effective concentration at which the antisense effect was exhibited. More specifically, strain S. aureus ATCC 29740 was cultured in MHB (BD) medium at 37 ° C for 18 hours and then diluted 1: 10000 in fresh MHB medium. P-PNA (stock solution, 400 μM in DW) was added to the diluent at a final concentration of 40 μM, 20 μM, 15 μM, 10 μM and 5 μM, respectively, and incubated at 37 ° C with shaking. P-PNA was not added to the control group. After 4 hours, the bacterial solution was partially taken and colony counting was performed. The results are shown in Fig.

As shown in FIG. 2, the P-PNA of the present invention was found to differ from the control group by about 10 μM.

Example  4. Antibiotic effects on various strains

To examine whether Pjyh-cmk1, Pjyh-deoD1, and Pjyh-smpB1 among the P-PNAs exhibiting excellent antisense effect in Example 2 exhibited antibacterial effects against various pathogenic bacteria, the same method as in Example 2 . The list of strains used in the experiment is shown in Table 3, and the results are shown in FIG. 3 and FIG.

Strains Description Staphylococcus aureus ATCC 29740 Staphylococcus hyicus ATCC 11249 Streptococcus dysgalactiae ATCC 27957 Streptococcus uberis ATCC 27958 Listeria monocytogenes ATCC 19117 Streptococcus equi ATCC 33398 Streptococcus zooepidemicus ATCC 43079 Escherichia coli O157: H7 ATCC 43894 Salmonella Typhimurium DT104 ATCC 2501 Pseudomonas aeruginosa ATCC 15442 Klebsiella pneumoniae ATCC 4352

As shown in FIG. 3 and FIG. 4, the P-PNA of the present invention has antibiotic effect against various Gram-positive bacteria and Gram-negative bacteria although there is a difference in degree for each P-PNA.

Example  5. Verification of Mechanism of Antibiotic Activity

RT-PCR was performed to determine whether the antibiotic activity of P-PNA as in Example 4 was due to interference of gene transcription or interference with mRNA expression. More specifically, S. aureus treated with 20 μM Pjyh-cmk1 and Pjyh-deoD1 ATCC 29740 strain was cultured in MHB for 3 hours, and RNA was extracted using an RNeasy mini kit (Quiagen). CDNA was synthesized using GoScript Reverse Transcription System (Promega) and real-time PCR (Rotor-Gene SYBR Green PCR kit, Quiagen) was performed using the cDNA as a template. The primer sequences used at this time are shown in Table 4.

Oligomer Target gene The nucleotide sequence (5'-3) ' cmkRealF1 cmk TCA AAA GAG CCA GTA CGT TCA TTC cmkRealR1 CGA TAT CGC GAC CAT CCA TTA C deodRealF1 deoD AGG TCA TTT CGC GCC TAT C deodRealR1 CGT GTG TAG TAG CAC CGA TTT gyr297F gyrB TTAGTGTGGGAAATTGTCGATAAT gyr574R AGTCTTGTGACAATGCGTTTACA STPYF 16s rRNA ACGGTCTTGCTGTCACTTATA STPYR2 TACACATATGTTCTTCCCTAATAA

The software provided by the Rotor-Gene real-time PCR cycler (Quiagen) automatically determines the C _T value based on the specified threshold, and then subtracts the C _T value obtained from the control group without P-PNA treatment, obtaining the ΔC _T, the mRNA gene-specific relative amounts of the control compared to P-PNA treated group was determined on the basis of this value. In addition, the the ΔC _T value for the one of the 16s rRNA of the test gene (reference gene) in the obtained gyrB and the ΔC _T value for the cmk or deoD was derived ΔΔC _T values, in the P-PNA treatment group using a value The relative mRNA changes of cmk or deoD and gyrB were compared. The results are shown in Table 5.

2 ^ ΔC _T ^a 2 ^ ΔΔC _T ^b P ^c cmk 1.30 ± 0.12 0.93 + 0.09 0.44 gyrB (reference gene 2) 1.34 ± 0.16 0.97 + 0.03 16s rRNA (reference gene 1) 1.38 ± 0.15 deoD 1.16 ± 0.22 0.98 + 0.02 0.8 gyrB (reference gene 2) 1.31 + - 0.12 0.97 + 0.08 16s rRNA (reference gene 1) 1.18 ± 0.08

As shown in Table 5, the amount of mk or deoD mRNA in the group treated with Pjyh-cmk1 or Pjyh-deoD1 of the present invention was not significantly different from that of the control group, and the mRNA of the other gene (gyrB) There was no significant difference between the two groups. Thus, it was confirmed that the P-PNA of the present invention does not affect the mRNA transcription amount and exhibits an antibiotic effect through an antisense mechanism that interferes with the expression of mRNA.

<110> SNU R & DB FOUNDATION <120> Novel PNA and antibacterial composition comprising the same <130> 78 <160> 21 <170> Kopatentin 2.0 <210> 1 <211> 10 <212> DNA <213> Artificial Sequence <220> <223> peptide nucleic acid <400> 1 tcatgcgtca 10 <210> 2 <211> 10 <212> DNA <213> Artificial Sequence <220> <223> peptide nucleic acid <400> 2 tcatttgtta 10 <210> 3 <211> 13 <212> DNA <213> Artificial Sequence <220> <223> peptide nucleic acid <400> 3 catagatagg cag 13 <210> 4 <211> 10 <212> DNA <213> Artificial Sequence <220> <223> peptide nucleic acid <400> 4 gcatgaacat 10 <210> 5 <211> 10 <212> DNA <213> Artificial Sequence <220> <223> peptide nucleic acid <400> 5 ccatccctta 10 <210> 6 <211> 10 <212> DNA <213> Artificial Sequence <220> <223> peptide nucleic acid <400> 6 ccattttctt 10 <210> 7 <211> 10 <212> DNA <213> Artificial Sequence <220> <223> peptide nucleic acid <400> 7 tcatactcac 10 <210> 8 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> carrier peptide <400> 8 Lys Phe Phe Lys Phe Phe Lys   1 5 10 <210> 9 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> carrier peptide <400> 9 Lys Phe Phe Lys Phe Phe Lys Phe Phe   1 5 <210> 10 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> carrier peptide <400> 10 Lys Phe Phe Lys Phe   1 5 <210> 11 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> carrier peptide <400> 11 Lys Phe Phe Lys   1 5 <210> 12 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> carrier peptide <400> 12 Lys Phe Phe Lys Phe Phe   1 5 <210> 13 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> carrier peptide <400> 13 Lys Phe Phe Lys Phe   1 5 <210> 14 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> carrier peptide <400> 14 Lys Phe Phe Lys   One <210> 15 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> carrier peptide <400> 15 Lys Phe Phe   One <210> 16 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> carrier peptide <400> 16 Phe Phe Arg Phe Phe Arg Phe Phe Arg Arg Leu Leu Arg   1 5 10 <210> 17 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> carrier peptide <400> 17 Leu Leu Lys Lys Leu Ala Lys Ala Leu   1 5 <210> 18 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> carrier peptide <400> 18 Lys Arg Arg Trp Pro Trp Trp Pro Trp Lys Lys   1 5 10 <210> 19 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> carrier peptide <400> 19 Lys Phe Lys Val Lys Phe Val Lys Lys   1 5 10 <210> 20 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> carrier peptide <400> 20 Leu Leu Lys Leu Leu Leu   1 5 10 <210> 21 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> carrier peptide <400> 21 Leu Leu Lys Lys Leu Ala Lys Ala Leu Lys   1 5 10

Claims (10)

A peptide nucleic acid (PNA) represented by at least one base sequence selected from the group consisting of SEQ ID NOS: 1 to 7.
A PNA-peptide complex represented by the following formula 1:
[Formula 1]
PNA-L-peptide
In the above formula (1), PNA is a peptide nucleic acid represented by at least one base sequence selected from the group consisting of SEQ ID NOS: 1 to 7,
L is a linker or a bond,
Wherein the peptide is represented by C- (BA) nD, wherein A is an uncharged amino acid or an amino acid analogue, B is one to three positively charged amino acids or amino acid analogues, and C is 0 to 4 Uncharged amino acid or amino acid analog, D is 0 to 3 positively charged amino acid or amino acid analog, and n is an integer of 1 to 10.
The PNA-peptide complex according to claim 2, wherein the peptide is represented by at least one amino acid sequence selected from the group consisting of SEQ ID NOS: 8 to 21.
The method of claim 2, wherein the PNA- peptide complexes _{Pjyh-cmk1 ((KFF) 3} K ( SEQ ID NO: 8) -L-tcatgcgtca (SEQ ID NO: 1)), ₃ K (SEQ ID NO: 8 Pjyh-deoD1 ((KFF) ) -L-tcatttgtta (SEQ ID NO: 2)), Pjyh-ligA1 ( (KFF) 3 K ( SEQ ID NO: 8) -L-ccatccctta (SEQ ID NO: 5)), Pjyh-pryH1 ( (KFF) 3 K ( SEQ ID NO: 8 ) -L-ccattttctt (SEQ ID NO: 6)) and _{Pjyh-smpB1 ((KFF) 3} K ( SEQ ID NO: 8) -L-tcatactcac (SEQ ID NO, characterized in that at least one member selected from the group consisting of 7)), PNA - peptide complex.
A composition for antibiosis comprising the PNA-peptide complex of claim 2 as an active ingredient.
6. The composition according to claim 5, wherein the antimicrobial composition is Staphylococcus ( Staphylococcus aureus) aureus , Staphylococcus hyicus , Streptococcus dysgalactiae), Streptococcus Ube-less (Streptococcus uberis), ekuyi Streptococcus (Streptococcus equi ), Streptococcus epidemicus zooepidemicus ), Listeria monocytogenes ( Listeria monocytogenes), Escherichia coli (Escherichia E. coli , Salmonella Typhimurium, Pseudomonas aeruginosa and Klebsiella spp. pneumoniae ). &lt; RTI ID = 0.0 &gt; 11. &lt; / RTI &gt;
The antimicrobial composition according to claim 5, wherein the antimicrobial composition is a pharmaceutical composition or a quasi-drug composition.
A pharmaceutical composition for preventing or treating a bacterial infection disease comprising the antibacterial composition of claim 5.
The method of claim 8, wherein the bacterial infection is a Staphylococcus aureus (Staphylococcus aureus , Staphylococcus hyicus , Streptococcus dysgalactiae , Streptococcus uberis uberis), ekuyi Streptococcus (Streptococcus equi), Streptococcus main epi Demi kusu (Streptococcus zooepidemicus), L. monocytogenes jeneseu (Listeria monocytogenes), Escherichia coli (Escherichia E. coli , Salmonella Typhimurium, Pseudomonas aeruginosa and Klebsiella spp. pneumoniae ). &lt; RTI ID = 0.0 &gt; 21. &lt; / RTI &gt;
9. The method of claim 8, wherein the bacterial infectious disease is selected from the group consisting of skin infection, food poisoning, otitis media, cystitis, peritonitis, urinary tract infection, mastitis, pneumonia, endocarditis, conjunctivitis, arthritis, endometritis, Or a pharmaceutically acceptable salt or solvate thereof.

Images